Psilocybin shows promise as a treatment for depression, though the evidence base remains limited and requires further rigorous study. The authors discuss the potential of psilocybin-assisted therapy to address mood disorders, emphasizing the need for more research to establish efficacy and safety. They highlight that while preliminary findings are encouraging, the field must proceed cautiously, with attention to methodological rigor and ethical considerations. The reply underscores the importance of continued investigation into psychedelic compounds as novel treatment options for mental health conditions.
A compound described as a 'nonpsychedelic psychedelic' reduced anxiety and depression in mice. This commentary questions whether findings from mouse models can reliably predict effects in humans, highlighting potential limitations in translating preclinical results to clinical treatments.